Preview

Пульмонология

Расширенный поиск

Роль и место комбинированной терапии препаратом серетид (сальметерол / флутиказона пропионат) в лечении бронхиальной астмы (обзор литературы)

Полный текст:

Об авторах

В. И. Петров
Волгоградская медицинская академия
Россия


И. В. Смоленов
Волгоградская медицинская академия
Россия


Н. А. Смирнов
Волгоградская медицинская академия
Россия


Список литературы

1. Global initiative for asthma. Global strategy for asthma management and prevention. Publ. N 95—3659. Washington: National Heart, Lung and Blood Institute, National In stitu te s of Health; 1995.

2. International consensus report on diagnosis and management of asthma. NIH Publ. N. 92—3091. National Heart, Lung and Blood Institute, National Institute of Health. Bethesda, Md; 1992.

3. Greening A.P., Ind. P.W., Northfield М., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219.

4. Taylor D.M. et al. Current autp a tien t management of asthma shous poor compliance with International Consensus Inidelines. Chest 1999; 116 (6): 1638—1645.

5. Cabana M.D. et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. J.A.M.A. 1999; 282 (15): 1458—1465.

6. Chung K.F. The complementory role of glucocorticosteroids and long-acting P-adrenergic agonists. Allergy 1998; 53 (suppl.42): 7—13.

7. Eickelberg О Roth М., Lorx R. et al. Ligand-independent activation of glucocorticoid receptor by P2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J. Biol. Chem. - 1999; 274: 1005.

8. Baraniuk L, Ali М., Brody D. et al. Glucocorticoids induce P2 - adrenergic receptor function in human nasal mucosa. Am. J. Respir. Crit. Care Med. 1997; 155: 704.

9. Pang L., Knox A.J. Synergistic inhibition by p 2-adrenoceptor agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smoothmuscle cells. Am. J. Respir. Cell Mol. Biol. 2000; 23: 79.

10. Pang L.H., Knox A.J. Inhibition by p 2 -adrenoceptor agonists and dexa-methasone on TNFalpha stimulated eotaxin release from human airway smooth muscle cells. Respir. Med. 1999; 54 (suppl.): A6.

11. Oddera S., Silvestri M ., Testi R., Rossi G.A. Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation. Respiration 1998; 65: 199.

12. Anenden V., Egemba G., Kessel B. et al. Salmeterol facilitation of fluticasone-induced apoptosis in eosinophils of asthmatics preand post-antigen challenge [abstract]. Eur. Respir. J. 1998; 12 (suppl. 28): 157s.

13. Mak J.C.W., Nishikawa М., Barnes P.J. Glucocorticosteroids increase p2 -adrenergic receptor transcription in human lung. Am. J. Physiol. 1995; 268: L41.

14. Mak J.C.W., Nishikawa М., Shirasaki H. et al. Protective effects of a glucocorticoid on downregulation of pulmonary p2-adrenergic receptors in vivo. J. Clin. Invest. 1995; 96: 99.

15. Proud D., Reynolds C.J., Lichtenstein L.M. et al. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration. Clin. Exp. Allergy. 1998; 28: 868.

16. Bissonnette E.Y., Befus D. Anti-inflammatory effect of p2 — agonists: inhibition of TNF-alpha release from human mast cells. J. Allergy Clin. Immunol. 1997; 100: 825.

17. Butchers P.R., Vardey C.J., Johnson M. Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung. Br. J. Pharmacol. 1991; 104: 672.

18. Nials A.T., Ball D.I., Butchers P.R. et al. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur. J. Pharmacol. 1994; 251: 127.

19. Chong L .K , Cooper E., Vardey C.J., Peachell P.T. Salmeterol inhibition of mediator release from human lung mast cells by ß-adrenoceptor-dependent and independent mechanisms. Br. J. Pharmacol. 1998; 123: 1009.

20. Dowling R.B., Johnson M., Cole P J ., Wilson R. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur. Respir. J. 1998; 11: 86.

21. Dowling R.B., Rayner C.F.J., Rutman A. et al. Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Am. J. Respir. Crit. Care Med. 1997; 155: 327.

22. Chapman K.R., Ringdal N., Backer V. et al. Salmeterol and fluticasone propionate (5 0 /2 5 0 jig) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can. Respir. J. 1999; 6 (1): 45—51.

23. Bateman E.D., Britton M., Carrillo J. et al. S a lm e tero l/flu tic a - sone propionate combination inhaler: a new, effective and well tolerated tre a tm en t of asthma. Clin. Drug. Invest. 1998; 16: 193—201.

24. Adkins J.C., McTavish D. Salmeterol: review of its pharmacological properties and clinical efficacy in the management of children with asthma. Drugs 1997; 54: 331-354.

25. Holliday S .M., Flauds D., Sorkin E.M. Inhaled fluticasone propionate: a review of its pharmocodynamic and pharmacokinetic properties, and theraputic use in asthma. Drugs 1994; 47 (2): 318—331.

26. Jarvis B., Faulds D. Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosage <500µg /day in adults and adolescents with mild to moderate asthma. Drugs 1999; 57: 769—803.

27. Dahl R. Salmeterol and fluticasone propionate in the treatment of asthma symptoms. Eur. Respir. Rev. 1997; 7: 338—343.

28. Johnson M. Development of fluticasone propionate and comparison with o ther inhaled corticosteroids. J. Allergy Clin. Immunol. 1998; 101 (4, pt 2, supp l.1): S434—S439.

29. Spenser C.M., Jarvis B. Salmeterol/fluticasone propionate combination. Drugs 1999; 57: 933—940.

30. Shapiro G., Lumry W., Wolfe J. et al. Combined salmeterol 50 µg and fluticasone propionate 250 µg in the Diskus device for the treatment of asthma. Am. J. Respir. Crit. Care Med. 2000; 161: 527—534.

31. Man C.Y., Kirby S.M., McRae J. et al. Systemic pharmacodynamic effects of salmeterol in the salmeterol/FP combination Diskus inhaler [absract no. Р1073]. Eur. Respir. J. 1996: 9 (suppl.23): 164s.

32. Gross G., Woodring A., Prillaman В. et al. Efficacy and safety of the salmeterol / fluticasone propionate ( 50 / 100 µg) dry powder combination inhaler in patients with asthma. Ibid.1998; 12 (suppl. 28): 156s.

33. Salmeterol/fluticasone propionate prescribing information. Uxbridge: Glaxo; 1999 Jul 27: 7.

34. Aubier M., Pieters W.R., Schlosser N.J.J. et al. Salmeterol/fluticasone propionate (50/500 µg) in combination in a Diskus inhaler (Seretid) is effective and safe in the treatment of steroiddependent asthma. Respir. Med. 1999; 93: 876-884.

35. Van de Berg N.J., Ossip M.S., Hederos C.A. et al. Salmeterol / fluticasone propionate (50/100 µg) in combination in a Diskus™ inhaler (Seretid™) is effective and safe in children with asthma. Pediatr. Pulmonol. 2000; 30: 97—105.

36. Kavuru M., Melamed J., Greoss G. et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the tre a tm en t of asthma: a randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 2000; 105 (6, pt 1): 1108—1116.

37. LaForce C., Woodring A., Baitinger L. et al. Salmeterol 50 mcg /fluticasone propionate lOOmcg Diskus combination product demo n s tra tes improvements in lung function regardless of baseline corticosteroid therapy [abstract no. 35]. Ibid. (1, pt 2): S I2.

38. Pearlman D., Baitinger L., Woodring A. et al. Salmeterol 50 mcg/fluticasone propionate 250 mcg Diskus combination product demonstrates improvements in lung function regardless of baseline corticosteroid therapy [abstract]. Am. J. Respir. Crit. Care Med. 2000; 161 (3, pt 2): A 196.

39. Wolfe J., Bell T., Raphael G. et al. Efficacy of the salmeterol/fluticasone propionate dry powder combination product in the Diskus: a stratified study in patients on salmeterol alone or inhaled corticosteroids [abstract no. 879]. J. Allergy Clin. Immunol. 1999: 103.(1, pt 2): S228.

40. Reese P.R., Mahajan P., Woodring A. Salmeterol/fluticasone propionate combination product improves quality of life in asthma patients [abstract no. P0325] Eur. Respir. J. 1998; 12 (suppl.28): 35s.

41. Reese P.R., Mather D.B., Mahajan P. et al. Combination of salmelerol/fluticasone propionate via Diskus improves quality of life in asthma patients. J. Allergy Clin. Immunol. 1999; 103 (1, pt 2): 69.

42. Jenkins C., Woolcock A.J., Saarelainen P. et al. Salmleterol/fluticasone propionate combination therapy 50/250 µg twice daily is more effective than budesonide 800 µg twice daily in treating moderate to severe asthma. Respir. Med. 2000: 94: 715—723.

43. Jenkins C., Woolcock A., Saarelainen P. et al. Advair/Seretide (satmeterol 50 mcg / fluticasone propionate 250 mcg bid) compared with budesonide (800 mcg bid) during he first week of treatment of moderate asthma [abstract no. 493]. J. Allergy Clin. Immunol. 2000; 105 (1, pt 2): S 161.

44. Juniper E.F., Jenkins C., Price M.J. et al. Quality of life of asthma patients treated with salmeterol/fluticasone propionate combination product and budesonide. In: Annual Congress European respiratory society. Madrid, 1999, Oct. 9—13. Madrid; 1999. abstr. no. P2460.

45. Ringdal N., Chuchalin A.G., Chovan L. et al. A comparison of Advair/Seretide (salmeterol 50 (mcg)/fluticasone propionate 250 (mcg bid) with formoterol 12 (mcg) + budesonid 800 (mcg bid in moderate-severe asthma [abstract]. Am. J. Respir. Crit. Care Med. 2000; 161 (3): A 196.

46. Nelson H.S., Busse W.W., Kerwin E. et al. Fluticasone propionate / salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J. Allergy Clin. Immunol. 2000; 106 (6): 1088—1095.

47. Lundback B., Pieters W.R.{ Johansson G. et al. Cost-effectiveness analyses of s a lm e te ro l/flu tic a so n e propionate combination product and fluticasone propionate in patients with a sthma. I: Introduction and overview. PharmacoEconomics 1999; 16 (suppl.2): 1—8.

48. Pieters W.R., Lundback B., Johansson G. et al. Cost-effectiveness analyses of sa lm e te ro l/flu tic a so n e propionate combination product and fluticasone propionate in patients with asthma. II: Study methodologies. Ibid. 9—14.

49. Johansson G., Price M.J., Sondhi S. Cost-effectiveness analysis of salmeterol/ fluticasone propionate 50/100 mg vs fluticasone propionate 100 M g in adults and adolescents with asthma III: Results. Ibid. 15—21.

50. Palmqvist M., Price M.J., Sondhi S. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/250 mg vs fluticasone propionate 250 mg in adults and adolescents with asthma IV: Results. Ibid. 23—28

51. Pieters W.R., Lundback B., Sondhi S. et al. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/500 µg vs fluticasone propionate 500 jig in adults and adolescents with asthma V: Results. Ibid. 29—34.

52. Lundback B., Jenkins C., Price M.J., Thwaites M.A. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micrograms twice daily and budesonide 800 micrograms twice daily in the tre a tm en t of adults and adolescents with asthma. Respir. Med. 2000; 94: 724.

53. Pieters W.R., Wilson K.K., Smith H.C.E., Tamminga J.J. Costeffectiveness of fluticasone propionate/salmeterol combination product and fluticasone propionate / montelukast in asthma. Am. J. Respir. Crit. Care Med. 2001; 163 (5, pt 2): A643.

54. Advair Diskus (fluticasone propionate and salmeterol) product information. Glaxo Wellcome Inc. Research. Triangle Park. NC; 2000 Aug: 30.

55. British National Formulary. No. 40. London: The Pharmaceutical Press; 2000. 772.

56. Ashurst I.C., Gordon P. Consistent dose delivery from a new metered dose inhaler contaning a combination of salmeterol and fluticasone propionate in HFA 134A [ab strac t no. P2295]. Eur. Respir. J. 1999; 14 (suppl.30): 341S.

57. British Thoracic Society, National Asthma Compaign, Royal College of Phyisicians of London, et al. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52 (supp l.l): S I—S21.

58. Bateman E.D., Bousquet Braunstein G.L. Is overall asthma control being achieved? A hypothesis-generating study. Eur. Respir. J. 2001; 17: 589—595.

59. Nielsen L.P., Pedersen B., Faurschou P. et al. Salmeterol reduces the need for inhaled corticosteroid in steroid dependent asthmatics. Respir. Med. 1999; 93 (12): 863—868.

60. Clark N., Jones P., Keller S., Vermeire P. Patient factors and compliance with asthma therapy. Ibid. 856—862.


Для цитирования:


Петров В.И., Смоленов И.В., Смирнов Н.А. Роль и место комбинированной терапии препаратом серетид (сальметерол / флутиказона пропионат) в лечении бронхиальной астмы (обзор литературы). Пульмонология. 2001;(3):99-107.

For citation:


Petrov V.l., Smolenov I.V., Smirnov N.A. A role and a site of a combined therapy with Seretid (salmeterol/fluticazone propionate) in bronchial asthma treatment (review). PULMONOLOGIYA. 2001;(3):99-107. (In Russ.)

Просмотров: 5


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)